Processing

Please wait...

Settings

Settings

Goto Application

1. CA2693436 - PREPARATION OF N-ALKYLATED OPIATES BY REDUCTIVE AMINATION

Office
Canada
Application Number 2693436
Application Date 16.06.2008
Publication Number 2693436
Publication Date 22.01.2009
Publication Kind A1
IPC
C07D 489/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
489Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro furan ring systems, e.g. derivatives of -morphinan of the formula:
02with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
C07D 489/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
489Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro furan ring systems, e.g. derivatives of -morphinan of the formula:
06with a hetero atom directly attached in position 14
08Oxygen atom
CPC
A61P 25/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
04Centrally acting analgesics, e.g. opioids
C07D 489/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
489Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
02with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
C07D 489/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
489Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
06with a hetero atom directly attached in position 14
08Oxygen atom
Applicants MALLINCKRODT INC.
Inventors GROTE, CHRISTOPHER W.
ORR, BRIAN
JIANG, TAO
CANTRELL, GARY L.
Priority Data 60/950,127 17.07.2007 US
Title
(EN) PREPARATION OF N-ALKYLATED OPIATES BY REDUCTIVE AMINATION
(FR) PREPARATION D'OPIACES N-ALKYLES PAR AMINATION REDUCTRICE
Abstract
(EN)
The present invention is directed to the reduction of an N-imine moiety or a hemiaminal moiety of a morphinan in the presence of a ruthenium, rhodium, or iridium asymmetric catalyst and a hydrogen source.